Drug intelligence / Profile preview

VGLCR

Development stage: Preclinical
Lead developer: noiVita
Modality: Small Molecules
Administration: Oral

Overview

VGLCR is an experimental oral nutraceutical combination formulation designed to counteract the early degenerative changes associated with glaucoma. The composition includes vitamin D3, gastrodin (the active ingredient of *Gastrodia elata*), lycopene, vitamin C, and blackcurrant extract, formulated using the patented FM-LipoMatrix® technology to enhance delivery. VGLCR acts as a neuroprotective agent for retinal ganglion cells (RGCs) by counteracting reactive oxygen species (ROS) production, inhibiting apoptotic cycles (via p53, Bax, and Annexin V modulation), and regulating key intracellular signaling pathways such as p38 MAPK, JNK, and ERK. Research conducted at the University of Eastern Piedmont has demonstrated its potential to prevent and restore retinal damage in both in vitro mouse RGC models and ex vivo bovine eyecup preparations.

Other names: vitamin D3 + gastrodin + lycopene + vitamin C + blackcurrant extract

Targets

OPA1 (OPA1 mitochondrial dynamin-like GTPase)SIRT1 (NAD-dependent protein deacetylase sirtuin-1)JNK (Mitogen-activated protein kinase kinase kinase family)MAPK3 (Mitogen-activated protein kinase 1)MMP9 (Matrix metalloproteinase-9)MAPK14 (p38 mitogen-activated protein kinase alpha)TP53 (Cellular Tumor Antigen p53 R175H)NOS2 (Nitric Oxide Synthase 2)BAX (Apoptosis regulator BAX)

Beyond the preview

Go deeper on VGLCR.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VGLCR.

Explore the full profile